MENU
JANX
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION
Janux Therapeutics (JANX) Ownership - Who owns Janux Therapeutics?
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer... Show more
Profile
Industry
N/A
Address
10955 Vista Sorrento Parkway
Phone
+1 858 751-4493
Employees
64
Web
https://www.januxrx.com
Details
Group
Domestic Stock Funds
Category
Biotechnology
Capitalization
1.37B
P/E Ratio
N/A
Total Cash
1.01B
Projected Growth
N/A
Total Debt
22.61M
Revenue
9.34M
Risk (Beta)
3.29
Dividend Yield
N/A
Total Cash/Share
16.88
Total Debt/Equity
N/A
Revenue/Share
0.01 USD as % of share price
Fundamentals
JANX
Capitalization
1.37B
P/E Ratio
N/A
Risk (Beta)
3.29
Dividend Yield
N/A
Total Cash
1.01B
Total Cash/Share
16.88
Total Debt
22.6M
Total Debt/Equity
N/A
Projected Growth (PEG Ratio)
N/A
Revenue/Share (as % of the share price)
0.01%
Revenue
9.34M
ROE
N/A
Book Value
1.01B
P/B Ratio
1.39
Cash Flow
N/A
Earnings
-1.36
Average Daily Volume YTD
N/A
Common Shares Outstanding - Security Level
59K
Current Ratio
58.47
Current Revenue Per Employee
5776.32
Dividends Per Share - Security
N/A
EBITDA
-111.54M
Float
N/A
Float - Current
N/A
Gross Income Margin
N/A
Revenue To Assets
-8.94
Shares Held By Institutions
2.83B
Shares Outstanding - Current
60.1M
Total Liabilities
38.3M
Total Volume MTD
N/A
Value
-1
Gain YTD
-57.359
View a ticker or compare two or three
VS
VS
Show more...
Interact to see
Advertisement
Advertisement
A.I.Advisor
published price charts
These past five trading days, the stock lost 0.00% with an average daily volume of 0 shares traded.The stock tracked a drawdown of 0% for this period. JANX showed earnings on August 07, 2025. You can read more about the earnings report here.
A.I. Advisor
published General Information
General Information
Industry Biotechnology
Profile
Fundamentals
Details
Industry
N/A
Address
10955 Vista Sorrento Parkway
Phone
+1 858 751-4493
Employees
64
Web
https://www.januxrx.com